Research Topics
Genomes and GenesSpecies | Robert G MillerSummaryAffiliation: California Pacific Medical Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Carrell-Krusen Symposium invited lecture. Clinical trials in motor neuron diseasesR G Miller
California Pacific Medical Center, San Francisco 94115, USA
J Child Neurol 14:173-9. 1999..The first clinical trials in spinal muscular atrophy are currently underway. A number of other developments have raised the quality of clinical trials, which should improve their productivity and efficiency in the future...- Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on ResearchR G Miller
Chairman Clinical Trials Consortium for the Research Group on Motor Neuron Diseases, World Federation of Neurology, Forbes Norris MDA ALS Center, Department of Neurology, California Pacific Medical Center, San Francisco 94115, USA
J Neurol Sci 169:2-12. 1999..In 1994 consensus guidelines were developed for conducting clinical trials in ALS. With growing experience in clinical trials, it has become clear that a number of further guidelines were needed... - Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosisR G Miller
Department of Neurology, California Pacific Medical Center, San Francisco, USA
Neurology 56:843-8. 2001..Preclinical and clinical studies of gabapentin in patients with ALS led the authors to undertake a phase III randomized clinical trial... - Examining the evidence about treatment in ALS/MNDR G Miller
Department of Neurology, California Pacific Medical Center, San Francisco 94115, USA
Amyotroph Lateral Scler Other Motor Neuron Disord 2:3-7. 2001..A.R.E., is also described as a methodology for measuring clinical outcomes, and some early results are presented. The evidence on riluzole indicates effectiveness in prolonging survival with a good safety profile... - A placebo-controlled trial of gabapentin in spinal muscular atrophyR G Miller
Department of Neurology, California Pacific Medical Center, Forbes Norris MSDA ALS Center, 2324 Sacramento Street, 150, San Francisco, CA 94115, USA
J Neurol Sci 191:127-31. 2001..To evaluate the efficacy of gabapentin in increasing muscle strength of patients with spinal muscular atrophy (SMA)... - Fatigue and therapeutic exerciseRobert G Miller
Department of Neurosciences, California Pacific Medical Center, 2324 Sacramento Street, 111 San Francisco, CA 94115, USA
J Neurol Sci 242:37-41. 2006..In this paper, we review recent studies of fatigue in common neurologic conditions and discuss therapeutic interventions. In particular, the role of therapeutic exercise is examined in both health and disease... - Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS)Rongzhen Zhang
University of California, San Francisco, San Francisco, CA 94110, USA
J Neuroimmunol 206:121-4. 2009..These data suggest that systemic LPS levels and activated monocyte/macrophages may play significant roles in the pathogenesis of sALS... - Gene expression profiling in peripheral blood mononuclear cells from patients with sporadic amyotrophic lateral sclerosis (sALS)Rongzhen Zhang
University of California, San Francisco, San Francisco, CA 94110, USA
J Neuroimmunol 230:114-23. 2011..Similar patterns of gene expression were reproduced in LPS stimulated PBMCs from healthy controls. These data suggest that chronic monocyte/macrophage activation may be through LPS/TLR4-signaling pathways in ALS... - MCP-1 chemokine receptor CCR2 is decreased on circulating monocytes in sporadic amyotrophic lateral sclerosis (sALS)Rongzhen Zhang
University of California, San Francisco, San Francisco General Hospital, San Francisco, CA 94110, USA
J Neuroimmunol 179:87-93. 2006..Defective monocyte/macrophages may play an active role in sALS... - A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALSPaul H Gordon
Department of Neurology, Columbia University, New York, USA
Amyotroph Lateral Scler 9:212-22. 2008..This phase II design was efficient, leading to treatment selection after just 60 patients, and can be used in other phase II trials to assess different agents... - Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trialPaul H Gordon
Department of Neurology, Columbia University, New York, NY, USA
Lancet Neurol 6:1045-53. 2007..Several trials are planned or are in progress to assess whether minocycline slows human neurodegeneration. We aimed to test the efficacy of minocycline as a treatment for amyotrophic lateral sclerosis (ALS)... - Outcomes research in amyotrophic lateral sclerosis: lessons learned from the amyotrophic lateral sclerosis clinical assessment, research, and education databaseRobert G Miller
Forbes Norris MDA ALS Research Center, California Pacific Medical Center 94115, San Francisco, CA, USA
Ann Neurol 65:S24-8. 2009..To examine the care of patients with ALS following the publication of the standardized recommendations for the management of patients with amyotrophic lateral sclerosis (ALS) published in 1999 by the American Academy of Neurology... - A comparison of maximal inspiratory pressure and forced vital capacity as potential criteria for initiating non-invasive ventilation in amyotrophic lateral sclerosisMichelle Mendoza
Forbes Norris MDA ALS Research Center, San Francisco, CA 94115, USA
Amyotroph Lateral Scler 8:106-11. 2007..For patients with clinical signs and symptoms needing treatment with NIV, a MIP< -60 cm H(2)O allows US clinicians to obtain non-invasive ventilatory support for patients earlier than if using the FVC criterion alone... - Improving efficiency of ALS clinical trials using lead-in designsDan H Moore
Research Institute CPMC, San Francisco, CA 94115, USA
Amyotroph Lateral Scler Other Motor Neuron Disord 5:57-60. 2004..A sample size reduction of 70% can be realized with variable lead-in compared to a parallel design... - Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS)Rongzhen Zhang
University of California, San Francisco, San Francisco General Hospital, 995 Potrero Avenue, Building 80, Ward 84, Box 0874, San Francisco, CA 94110, USA
J Neuroimmunol 159:215-24. 2005..These data are consistent with a disease model previously suggested for AD, wherein systemic immunologic activation plays an active role in sALS... - Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosisArie Gruzman
Bioconformatics Laboratory and Department of Neuroscience, California Pacific Medical Center Research Institute, San Francisco, CA 94107, USA
Proc Natl Acad Sci U S A 104:12524-9. 2007..Our results identify a shared molecular event involving a known target gene and suggest a common step in the pathogenesis between SALS and FALS... - Drug therapy in amyotrophic lateral sclerosisB Jane Distad
Department of Neurology, University of Washington Medical Center, 1959 NE Pacific Street, Seattle, WA 98195, USA
Phys Med Rehabil Clin N Am 19:633-51, xi-xii. 2008..The authors review the current understanding of the pathogenic mechanisms of ALS and approaches to treating the disease... - Gray matter perfusion correlates with disease severity in ALSRandall R Rule
4150 Clement Street 114Q, San Francisco, CA 94121, USA
Neurology 74:821-7. 2010..The presence of such a relationship would indicate a possible role for ASL perfusion as a marker of disease severity and upper motor neuron involvement in ALS... - Role of fatigue in limiting physical activities in humans with neuromuscular diseasesRobert G Miller
Department of Neurology, California Pacific Medical Center, San Francisco, California 94115, USA
Am J Phys Med Rehabil 81:S99-107. 2002..Examples of both central and peripheral fatigue in various neuromuscular diseases and other disorders are presented, including metabolic myopathy, chronic fatigue syndrome, postpolio syndrome, and amyotrophic lateral sclerosis... - Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)Robert G Miller
Forbes Norris ALS Research Center, California PacificMedical Center, San Francisco, USA
Cochrane Database Syst Rev 3:CD001447. 2012..Riluzole is approved for the treatment of amyotrophic lateral sclerosis in most countries. Questions persist about its clinical utility because of high cost and modest efficacy... - "You have shown me my end": attitudes toward presymptomatic testing for familial amyotrophic lateral sclerosisJoanna H Fanos
Research Institute and Department of Pediatrics, California Pacific Medical Center, San Francisco, California 94115, USA
Am J Med Genet A 129:248-53. 2004.... - Detecting neurobehavioral changes in amyotrophic lateral sclerosisAlison B Grossman
Department of Neurology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
Amyotroph Lateral Scler 8:56-61. 2007..The FrsBe is useful for detecting behavioral change and abnormalities in patients with ALS... - ALS trial design: expectation and realityRobert G Miller
California Pacific Medical Center, San Francisco, USA
Amyotroph Lateral Scler Other Motor Neuron Disord 5:52-4. 2004 - Neuromuscular diseases: therapeutic advancesRobert G Miller
California Pacific Medical Center, 2324 Sacramento Street, San Francisco, CA 94115, USA
Lancet Neurol 7:12-4. 2008 - Classical and emergent measures for clinical trials in ALSRobert G Miller
San Francisco, CA, USA
Amyotroph Lateral Scler Other Motor Neuron Disord 3:S1-2. 2002 - Measurement of strength: summaryRobert G Miller
California Pacific Medical Center, San Francisco, CA, USA
Amyotroph Lateral Scler Other Motor Neuron Disord 3:S51-4. 2002 - Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trialP Nigel Leigh
Department of Neurology, Institute of Psychiatry, London, UK
Amyotroph Lateral Scler Other Motor Neuron Disord 5:84-98. 2004.... - Drug therapy for amyotrophic lateral sclerosis: Where are we now?Gregory T Carter
Muscular Dystrophy Association Amyotrophic Lateral Sclerosis Center, University of Washington School of Medicine, Seattle, WA 98195, USA
IDrugs 6:147-53. 2003..We indicate current and future directions in research and clinical trials, and also argue that a logical next step for clinical trials in ALS should be combination drug treatment... - NIPPV: a treatment for ALS whose time has comeTerry D Heiman-Patterson
Neurology 67:736-7. 2006 - Hope in palliative care: from narcissism to self-transcendence in amyotrophic lateral sclerosisJoanna H Fanos
Department of Pediatrics, Dartmouth Medical School, Dartmouth Hitchcock Medical Center Lebanon, New Hampshire 03756, USA
J Palliat Med 11:470-5. 2008..Our research explored the meaning of hope in individuals with ALS... - ALSFRS-RPaul H Gordon
Eleanor and Lou Gehrig MDA ALS Research Center, Neurological Institute, New York, NY 10032, USA
Amyotroph Lateral Scler Other Motor Neuron Disord 5:90-3. 2004..Unlike the other standard outcome measures currently employed, the ALSFRS-R is also a measure of global function... - Whole-genome analysis of sporadic amyotrophic lateral sclerosisTravis Dunckley
Translational Genomics Research Inst, Phoenix, AZ 85004, USA
N Engl J Med 357:775-88. 2007..Approximately 90% of persons with amyotrophic lateral sclerosis (ALS) have the sporadic form, which may be caused by the interaction of multiple environmental factors and previously unknown genes... - Promoting excellence in end-of-life care in ALSHiroshi Mitsumoto
The Elenor and Lou Gehrig MDA ALS Research Center, Columbia University Neurological Institute, New York, NY 10032, USA
Amyotroph Lateral Scler Other Motor Neuron Disord 6:145-54. 2005..Several public policy changes that will improve coverage for medical care, hospice, and caregiver costs are also reviewed. More clinical evidence is needed on how to provide optimal end-of-life care specifically in ALS... - Factors correlated with NPPV use in ALSCarlayne E Jackson
University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
Amyotroph Lateral Scler 7:80-5. 2006..The findings may be useful in designing prospective studies to examine the factors which might explain the underutilization of NPPV and the optimal use of this treatment...
Research Grants
- Phase III Trial of Minocycline in ALS-II Data CenterRobert Miller; Fiscal Year: 2006..The details of data management are described, including the methods for quality control, security and information technology. Finally, the analytic plan is described in full. ..
- Phase III Trial of Minocycline in ALS-II Data CenterRobert Miller; Fiscal Year: 2007..The details of data management are described, including the methods for quality control, security and information technology. Finally, the analytic plan is described in full. ..